Skip to main content

Kodiak Sciences Inc.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

KOD$108.06+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included in signature page)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Victor Perlroth and John Borgeson, jointly and severally, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

SignatureTitleDate
/s/ Victor PerlrothChairman and Chief Executive Officer(Principal Executive Officer)March 31, 2026
Victor Perlroth, M.D.
/s/ John BorgesonChief Financial Officer(Principal Financial and Accounting Officer)March 31, 2026
John Borgeson
/s/ Felix J. BakerDirectorMarch 31, 2026
Felix J. Baker, Ph.D.
/s/ Charles BancroftDirectorMarch 31, 2026
Charles Bancroft
/s/ Bassil I. DahiyatDirectorMarch 31, 2026
Bassil I. Dahiyat, Ph.D.
/s/ Richard S. LevyDirectorMarch 31, 2026
Richard S. Levy, M.D.
/s/ Robert A. ProfusekDirectorMarch 31, 2026
Robert A. Profusek, J.D.
/s/ Taiyin YangDirectorMarch 31, 2026
Taiyin Yang, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.